Nanjing KAEDI Biotherapeutics

Nanjing KAEDI Biotherapeutics is a clinical-stage biotechnology company headquartered in Nanjing, China, specializing in the development of next-generation CAR-T cell therapies for solid tumors and hematological malignancies. The company utilizes its proprietary KD-CART platform to engineer T cells with enhanced persistence and efficacy within the immunosuppressive tumor microenvironment. Its lead candidate, KD-033, is a GPC3-targeted CAR-T therapy currently being evaluated in clinical trials for hepatocellular carcinoma. KAEDI's pipeline also includes programs targeting Claudin 18.2 and NKG2D ligands, reflecting a strategic focus on high-unmet-need oncology indications. The company has established comprehensive R&D and manufacturing infrastructure to support its transition from discovery to clinical development. Backed by prominent venture capital firms, KAEDI is led by a management team with extensive experience in immunology and cell engineering.